375 related articles for article (PubMed ID: 15016779)
1. Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial.
Ricci G; Cerneca F; Simeone R; Pozzobon C; Guarnieri S; Sartore A; Pregazzi R; Guaschino S
Hum Reprod; 2004 Apr; 19(4):838-48. PubMed ID: 15016779
[TBL] [Abstract][Full Text] [Related]
2. Effect of urinary versus recombinant follicle-stimulating hormone on platelet function and other hemostatic variables in controlled ovarian hyperstimulation.
Bar J; Orvieto R; Lahav J; Hod M; Kaplan B; Fisch B
Fertil Steril; 2004 Dec; 82(6):1564-9. PubMed ID: 15589861
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH.
Ricci G; Tamaro G; Simeone R; Giolo E; Nucera G; De Seta F; Guaschino S
Hum Reprod; 2001 Mar; 16(3):449-56. PubMed ID: 11228210
[TBL] [Abstract][Full Text] [Related]
4. The use of a decremental dose regimen in patients treated with a chronic low-dose step-up protocol for WHO Group II anovulation: a prospective randomized multicentre study.
Hugues JN; Cédrin-Durnerin I; Howles CM; ; Amram M; Angelini A; Balen A; Barbereau D; Birkhauser M; Boujenah A; De Leo V; De Placido G; Dessole S; Favrin S; Ferrazi E; Gay C; Germond M; Hedon B; Hocke C; Jolly C; Lamarca-Roth E; Lanzone A; Marchand F; Marcolin G; Mascaretti G; Moreau L; Massobrio M; Nappi C; Pardi G; Pennehouat G; Porcu E; Seibert M; Selvaggi L; Thiers D; Venturini P
Hum Reprod; 2006 Nov; 21(11):2817-22. PubMed ID: 16877376
[TBL] [Abstract][Full Text] [Related]
5. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
6. Influence of smoking during pregnancy on haemostasis in healthy full term neonates.
Mitsiakos G; Giougi E; Papaioannou G; Karagianni P; Papadakis E; Nikolaidis N
Thromb Res; 2009; 123(3):476-81. PubMed ID: 18417192
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women.
Callejon DR; Franceschini SA; Montes MB; Toloi MR
Maturitas; 2005; 52(3-4):249-55. PubMed ID: 16257613
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of highly purified urinary FSH versus recombinant FSH in volunteers undergoing controlled ovarian stimulation for in vitro fertilization: a randomized, multicenter, investigator-blind trial.
Baker VL; Fujimoto VY; Kettel LM; Adamson GD; Hoehler F; Jones CE; Soules MR
Fertil Steril; 2009 Apr; 91(4):1005-11. PubMed ID: 18367182
[TBL] [Abstract][Full Text] [Related]
9. Further characterization of the luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
Balasch J; Fábregues F; Tur R; Creus M; Casamitjana R; Peñarrubia J; Barri PN; Vanrell JA
Hum Reprod; 1995 Jun; 10(6):1377-81. PubMed ID: 7593500
[TBL] [Abstract][Full Text] [Related]
10. [Haemostatic and fibrinolytic variables in women with anorexia nervosa].
Sobieszczańska S; Rabe-Jabłońska J
Psychiatr Pol; 2005; 39(4):741-59. PubMed ID: 16237979
[TBL] [Abstract][Full Text] [Related]
11. Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study.
Erdem A; Erdem M; Atmaca S; Guler I
Fertil Steril; 2009 Jun; 91(6):2508-13. PubMed ID: 18692788
[TBL] [Abstract][Full Text] [Related]
12. Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating hormone.
Foong SC; Abbott DH; Lesnick TG; Session DR; Walker DL; Dumesic DA
Fertil Steril; 2005 May; 83(5):1377-83. PubMed ID: 15866572
[TBL] [Abstract][Full Text] [Related]
13. [Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins].
Ellenbogen A; David H; Libal Y; Ballas S
Harefuah; 1995 Dec; 129(11):455-6, 536. PubMed ID: 8846950
[TBL] [Abstract][Full Text] [Related]
14. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
[TBL] [Abstract][Full Text] [Related]
15. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders.
Berkkanoglu M; Isikoglu M; Aydin D; Ozgur K
Fertil Steril; 2007 Sep; 88(3):665-9. PubMed ID: 17292895
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.
Moon SY; Choi YS; Ku SY; Kim SH; Choi YM; Kang IS; Kim CH
J Obstet Gynaecol Res; 2007 Jun; 33(3):305-15. PubMed ID: 17578360
[TBL] [Abstract][Full Text] [Related]
17. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study.
Tarlatzis B; Tavmergen E; Szamatowicz M; Barash A; Amit A; Levitas E; Shoham Z
Hum Reprod; 2006 Jan; 21(1):90-4. PubMed ID: 16172149
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
Carone D; Caropreso C; Vitti A; Chiappetta R
J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
[TBL] [Abstract][Full Text] [Related]
20. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
